Summit appoints Ralf Rosskamp as chief medical officer

2 September 2015

Duchenne muscular dystrophy (DMD) specialist Summit Therapeutics (Nasdaq: SMMT) has appointed Ralf Rosskamp as chief medical officer.

Dr Rosskamp was most recently vice president of global clinical development at NPS Pharmaceuticals and oversaw the development of several rare disease drug candidates.

Glyn Edwards, chief executive of Summit, said: “Dr Rosskamp’s 25 years of drug development and regulatory expertise, especially his experience with rare and pediatric diseases, are a great fit with Summit and our clinical programs. He is joining at a really exciting time as we initiate Phase II trials in our utrophin modulator program for DMD and look forward to reporting data from our proof of concept Phase 2 trial of SMT19969 for CDI. We welcome him to the team.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK